Repaglinide: a novel oral antidiabetic agent.
Repaglinide is a novel oral antidiabetic agent, marking the development of a new class of drugs for type 2 diabetes. This article examines repaglinide and its position in the treatment of type 2 diabetes.
Nattrass
M
M
Diabetes Resource Centre, Selly Oak Hospital, Birmingham, UK.
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D002219:Carbamates / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000009:adverse effects
D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; D013453:Sulfonylurea Compounds; C072379:repaglinide